Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study

This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, open-label comparator study to investigate the efficacy and safety of esaxerenone (CS-3150), a novel non-steroidal mineralocorticoid receptor blocker, in Japanese patients with essential hypertension. Eligible patients (n...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Sadayoshi, Itoh, Hiroshi, Rakugi, Hiromi, Okuda, Yasuyuki, Yamakawa, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760614/
https://www.ncbi.nlm.nih.gov/pubmed/31113987
http://dx.doi.org/10.1038/s41371-019-0207-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760614/
https://www.ncbi.nlm.nih.gov/pubmed/31113987
http://dx.doi.org/10.1038/s41371-019-0207-x

Ejemplares similares